Advertisement

Stem Cell Reviews and Reports

, Volume 15, Issue 5, pp 619–636 | Cite as

Solid Tumors Challenges and New Insights of CAR T Cell Engineering

  • Safa Tahmasebi
  • Reza Elahi
  • Abdolreza EsmaeilzadehEmail author
Article

Abstract

Adoptive cell therapy using CAR T cells has emerged as a novel treatment strategy with promising results against B cell malignancies; however, CAR T cells have not shown much success against solid malignancies. There are several obstacles which diminish the efficacy of CAR T cells, but the immunosuppressive tumor microenvironment (TME) of the tumor stands out as the most important factor. TME includes Tumor-Associated Stroma, Immunosuppressive cells and cytokines, tumor hypoxia and metabolism, and Immune Inhibitory Checkpoints which affect the CAR T cell efficacy and activity in solid tumors. A precise understanding of the TME could pave the way to engineer novel modifications of CAR T cells which can overcome the immunosuppressive TME. In this review, we will describe different sections of the TME and introduce novel approaches to improve the CAR T cells potential against solid tumors based on recent clinical and preclinical data. Also, we will provide new suggestions on how to modify CARs to augment of CAR T cells efficacy. Since there are also some challenges beyond the TME that are important for CAR function, we will also discuss and provide data about the improvement of CAR T cells trafficking and delivery to the tumor site and how to solve the problem of tumor antigen heterogeneity.

Keywords

Immunotherapy Adoptive cell therapy Challenges Solid tumor Chimeric antigen receptor CAR T cell 

Notes

Author Contributions

ST and RE contributed to data gathering, writing the primary draft of the manuscript, and designing figures and Tables. AE contributed to the hypothesis, corresponding, scientific and structural editing, and verifying the manuscript before submission.

Funding Resources

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. 1.
    Xia, A.-L., Wang, X.-C., Lu, Y.-J., Lu, X.-J., & Sun, B. (2017). Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: Challenges and opportunities. Oncotarget., 8(52), 90521.Google Scholar
  2. 2.
    Chen, X., Han, J., Chu, J., Zhang, L., Zhang, J., Chen, C., et al. (2016). A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases. Oncotarget., 7(19), 27764.Google Scholar
  3. 3.
    Elahi, R., Khosh, E., Tahmasebi, S., & Esmaeilzadeh, A. (2018). Immune cell hacking: Challenges and clinical approaches to create smarter generations of chimeric antigen receptor T cells. Frontiers in Immunology, 9.  https://doi.org/10.3389/fimmu.2018.01717.
  4. 4.
    Junghans, R. P., Ma, Q., Rathore, R., Gomes, E. M., Bais, A. J., Lo, A. S., et al. (2016). Phase I trial of anti-PSMA designer CAR-T cells in prostate Cancer: Possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response. The Prostate., 76(14), 1257–1270.Google Scholar
  5. 5.
    Romero, D. (2018). Haematological cancer: Favourable outcomes with CAR T cells. Nature Reviews. Clinical Oncology, 15(2), 65.Google Scholar
  6. 6.
    Scarfò, I., & Maus, M. V. (2017). Current approaches to increase CAR T cell potency in solid tumors: Targeting the tumor microenvironment. Journal for Immunotherapy of Cancer., 5(1), 28.Google Scholar
  7. 7.
    Trédan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007). Drug resistance and the solid tumor microenvironment. Journal of the National Cancer Institute, 99(19), 1441–1454.Google Scholar
  8. 8.
    Frigault, M. J., Lee, J., Basil, M. C., Carpenito, C., Motohashi, S., Scholler, J., Kawalekar, O. U., Guedan, S., McGettigan, S. E., Posey, A. D., Ang, S., Cooper, L. J. N., Platt, J. M., Johnson, F. B., Paulos, C. M., Zhao, Y., Kalos, M., Milone, M. C., & June, C. H. (2015). Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunology Research, 3, 356–367.  https://doi.org/10.1158/2326-6066.CIR-14-0186.Google Scholar
  9. 9.
    Di, S., & Li, Z. (2016). Treatment of solid tumors with chimeric antigen receptor-engineered T cells: Current status and future prospects. Science China. Life Sciences, 59(4), 360–369.Google Scholar
  10. 10.
    Mirzaei, H. R., Rodriguez, A., Shepphird, J., Brown, C. E., & Badie, B. (2017). Chimeric antigen receptors T cell therapy in solid tumor: Challenges and clinical applications. Frontiers in Immunology, 8, 1850.Google Scholar
  11. 11.
    Lo, A., Wang, L.-C. S., Scholler, J., Monslow, J., Avery, D., Newick, K., O'Brien, S., Evans, R. A., Bajor, D. J., Clendenin, C., Durham, A. C., Buza, E. L., Vonderheide, R. H., June, C. H., Albelda, S. M., & Pure, E. (2015). Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells. Cancer Research, 75(14), 2800–2810.Google Scholar
  12. 12.
    Wang, L.-C. S., Lo, A., Scholler, J., Sun, J., Majumdar, R. S., Kapoor, V., Antzis, M., Cotner, C. E., Johnson, L. A., Durham, A. C., Solomides, C. C., June, C. H., Pure, E., & Albelda, S. M. (2014). Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunology Research, 2(2), 154–166.Google Scholar
  13. 13.
    Caruana, I., Savoldo, B., Hoyos, V., Weber, G., Liu, H., Kim, E. S., Ittmann, M. M., Marchetti, D., & Dotti, G. (2015). Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nature Medicine, 21(5), 524–529.Google Scholar
  14. 14.
    Nishio, N., & Dotti, G. (2015). Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors. Oncoimmunology., 4(2), e988098.Google Scholar
  15. 15.
    Koneru, M., O’Cearbhaill, R., Pendharkar, S., Spriggs, D. R., & Brentjens, R. J. (2015). A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16 ecto directed chimeric antigen receptors for recurrent ovarian cancer. Journal of Translational Medicine, 13(1), 102.Google Scholar
  16. 16.
    Zhang, L., Yu, Z., Muranski, P., Palmer, D., Restifo, N., Rosenberg, S., et al. (2013). Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy. Gene Therapy, 20(5), 575–580.Google Scholar
  17. 17.
    Mohammed, S., Sukumaran, S., Bajgain, P., Watanabe, N., Heslop, H. E., Rooney, C. M., Brenner, M. K., Fisher, W. E., Leen, A. M., & Vera, J. F. (2017). Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer. Molecular Therapy, 25(1), 249–258.Google Scholar
  18. 18.
    Adachi, K., Kano, Y., Nagai, T., Okuyama, N., Sakoda, Y., & Tamada, K. (2018). IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nature Biotechnology, 36(4), 346–351.Google Scholar
  19. 19.
    Arab, S., Kheshtchin, N., Ajami, M., Ashurpoor, M., Safvati, A., Namdar, A., Mirzaei, R., Mousavi Niri, N., Jadidi-Niaragh, F., Ghahremani, M. H., & Hadjati, J. (2017). Increased efficacy of a dendritic cell–based therapeutic cancer vaccine with adenosine receptor antagonist and CD73 inhibitor. Tumor Biology, 39(3), 1010428317695021.Google Scholar
  20. 20.
    Beavis, P. A., Milenkovski, N., Henderson, M. A., John, L. B., Allard, B., Loi, S., Kershaw, M. H., Stagg, J., & Darcy, P. K. (2015). Adenosine receptor 2A blockade increases the efficacy of anti–PD-1 through enhanced antitumor T-cell responses. Cancer Immunology Research, 3(5), 506–517.Google Scholar
  21. 21.
    Ligtenberg, M. A., Mougiakakos, D., Mukhopadhyay, M., Witt, K., Lladser, A., Chmielewski, M., Riet, T., Abken, H., & Kiessling, R. (2016). Coexpressed catalase protects chimeric antigen receptor–redirected T cells as well as bystander cells from oxidative stress–induced loss of antitumor activity. The Journal of Immunology., 196(2), 759–766.Google Scholar
  22. 22.
    Ninomiya, S., Narala, N., Huye, L., Yagyu, S., Savoldo, B., Dotti, G., Heslop, H. E., Brenner, M. K., Rooney, C. M., & Ramos, C. A. (2015). Tumor indoleamine 2, 3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood., 125(25), 3905–3916.Google Scholar
  23. 23.
    Newick, K., O'Brien, S., Sun, J., Kapoor, V., Maceyko, S., Lo, A., Pure, E., Moon, E., & Albelda, S. M. (2016). Augmentation of CAR T-cell trafficking and antitumor efficacy by blocking protein kinase a localization. Cancer Immunology Research, 4(6), 541–551.Google Scholar
  24. 24.
    Scheffel, M. J., Scurti, G., Simms, P., Garrett-Mayer, E., Mehrotra, S., Nishimura, M. I., & Voelkel-Johnson, C. (2016). Efficacy of adoptive T-cell therapy is improved by treatment with the antioxidant N-acetyl cysteine, which limits activation-induced T-cell death. Cancer Research, 76(20), 6006–6016.Google Scholar
  25. 25.
    Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009). Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies. The Journal of Experimental Medicine, 206(8), 1717–1725.Google Scholar
  26. 26.
    Ren, J., Zhang, X., Liu, X., Fang, C., Jiang, S., June, C. H., et al. (2017). A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget., 8(10), 17002.Google Scholar
  27. 27.
    John, L. B., Devaud, C., Duong, C. P., Yong, C. S., Beavis, P. A., Haynes, N. M., et al. (2013). Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clinical Cancer Research, 19(20), 5636–5646.Google Scholar
  28. 28.
    Rupp, L. J., Schumann, K., Roybal, K. T., Gate, R. E., Chun, J. Y., Lim, W. A., et al. (2017). CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Scientific Reports, 7(1), 737.Google Scholar
  29. 29.
    Liu, X., Ranganathan, R., Jiang, S., Fang, C., Sun, J., Kim, S., Newick, K., Lo, A., June, C. H., Zhao, Y., & Moon, E. K. (2016). A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors. Cancer Research, 76(6), 1578–1590.Google Scholar
  30. 30.
    Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., Tangsombatvisit, S., Grosso, J. F., Netto, G., Smeltzer, M. P., Chaux, A., Utz, P. J., Workman, C. J., Pardoll, D. M., Korman, A. J., Drake, C. G., & Vignali, D. A. A. (2012). Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Research, 72(4), 917–927.Google Scholar
  31. 31.
    Yoon, D. H., Osborn, M. J., Tolar, J., & Kim, C. J. (2018). Incorporation of immune checkpoint blockade into chimeric antigen receptor T cells (CAR-Ts): Combination or built-in CAR-T. International Journal of Molecular Sciences, 19(2), 340.Google Scholar
  32. 32.
    Fourcade, J., Sun, Z., Pagliano, O., Guillaume, P., Luescher, I. F., Sander, C., et al. 2012).CD8+ T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Research. 2011:canres. 2637.011.Google Scholar
  33. 33.
    Beavis, P. A., Henderson, M. A., Giuffrida, L., Mills, J. K., Sek, K., Cross, R. S., Davenport, A. J., John, L. B., Mardiana, S., Slaney, C. Y., Johnstone, R. W., Trapani, J. A., Stagg, J., Loi, S., Kats, L., Gyorki, D., Kershaw, M. H., & Darcy, P. K. (2017). Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. The Journal of Clinical Investigation., 127(3), 929–941.Google Scholar
  34. 34.
    Johnston, R. J., Comps-Agrar, L., Hackney, J., Yu, X., Huseni, M., Yang, Y., Park, S., Javinal, V., Chiu, H., Irving, B., Eaton, D. L., & Grogan, J. L. (2014). The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function. Cancer Cell, 26(6), 923–937.Google Scholar
  35. 35.
    Kershaw, M. H., Wang, G., Westwood, J. A., Pachynski, R. K., Tiffany, H. L., Marincola, F. M., Wang, E., Young, H. A., Murphy, P. M., & Hwu, P. (2002). Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Human Gene Therapy, 13(16), 1971–1980.Google Scholar
  36. 36.
    Long, A. H., Highfill, S. L., Cui, Y., Smith, J. P., Walker, A. J., Ramakrishna, S., el-Etriby, R., Galli, S., Tsokos, M. G., Orentas, R. J., & Mackall, C. L. (2016). Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas. Cancer Immunology Research, 4(10), 869–880.Google Scholar
  37. 37.
    Zhou, Q., Munger, M. E., Highfill, S. L., Tolar, J., Weigel, B. J., Riddle, M., Sharpe, A. H., Vallera, D. A., Azuma, M., Levine, B. L., June, C. H., Murphy, W. J., Munn, D. H., & Blazar, B. R. (2010). Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood., 116(14), 2484–2493.Google Scholar
  38. 38.
    Markley, J. C., & Sadelain, M. (2010). IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell–mediated rejection of systemic lymphoma in immunodeficient mice. Blood., 115(17), 3508–3519.Google Scholar
  39. 39.
    Yao, X., Ahmadzadeh, M., Lu, Y.-C., Liewehr, D. J., Dudley, M. E., Liu, F., Schrump, D. S., Steinberg, S. M., Rosenberg, S. A., & Robbins, P. F. (2012). Levels of peripheral CD4+ FoxP3+ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood., 119(24), 5688–5696.Google Scholar
  40. 40.
    Spear, P., Barber, A., Rynda-Apple, A., & Sentman, C. L. (2012). Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-gamma and GM-CSF. Journal of Immunology (Baltimore, Md. : 1950), 188(12), 6389–6398.Google Scholar
  41. 41.
    Chmielewski, M., & Abken, H. (2017). CAR T cells releasing IL-18 convert to T-bet high FoxO1 low effectors that exhibit augmented activity against advanced solid tumors. Cell Reports, 21(11), 3205–3219.Google Scholar
  42. 42.
    Marofi, F., Vahedi, G., Biglari, A., Esmaeilzadeh, A., & Athari, S. S. (2017). Mesenchymal stromal/stem cells: A new era in the cell-based targeted gene therapy of cancer. Frontiers in Immunology, 8, 1770.Google Scholar
  43. 43.
    Bhowmick, N. A., Neilson, E. G., & Moses, H. L. (2004). Stromal fibroblasts in cancer initiation and progression. Nature., 432(7015), 332–337.Google Scholar
  44. 44.
    Kakarla, S., Chow, K. K., Mata, M., Shaffer, D. R., Song, X.-T., Wu, M.-F., et al. (2013). Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Molecular Therapy, 21(8), 1611–1620.Google Scholar
  45. 45.
    Vlodavsky, I., Elkin, M., & Ilan, N. (2011). Impact of heparanase and the tumor microenvironment on cancer metastasis and angiogenesis: Basic aspects and clinical applications. Rambam Maimonides Medical Journal., 2(1).  https://doi.org/10.5041/RMMJ.10019.
  46. 46.
    Arvatz, G., Weissmann, M., Ilan, N., & Vlodavsky, I. (2016). Heparanase and cancer progression: New directions, new promises. Human Vaccines & Immunotherapeutics, 12(9), 2253–2256.Google Scholar
  47. 47.
    Bollard, C. M., Rössig, C., Calonge, M. J., Huls, M. H., Wagner, H.-J., Massague, J., Brenner, M. K., Heslop, H. E., & Rooney, C. M. (2002). Adapting a transforming growth factor β–related tumor protection strategy to enhance antitumor immunity. Blood., 99(9), 3179–3187.Google Scholar
  48. 48.
    Piri, Z., Esmaeilzadeh, A., & Hajikhanmirzaei, M. (2012). Interleukin-25 as a candidate gene in immunogene therapy of pancreatic cancer. Journal of Medical Hypotheses and Ideas., 6(2), 75–79.Google Scholar
  49. 49.
    Mirzaei, M. H., & Esmaeilzadeh, A. (2014). Overexpression of MDA-7/IL-24 as an anticancer cytokine in gene therapy of thyroid carcinoma. Journal of Medical Hypotheses and Ideas., 8(1), 7–13.Google Scholar
  50. 50.
    Esmaeilzadeh, A., Ebtekar, M., Biglari, A., & Saraf, S. (2014). Anti-proliferative effect of rmIL-27 protein on 4T1 mouse breast cancer cells as a candidate for cancer immunotherapy. ZUMS Journal., 22(91), 52–60.Google Scholar
  51. 51.
    Zhang, C., Liu, J., Zhong, J. F., & Zhang, X. (2017). Engineering CAR-T cells. Biomarker Research, 5(1), 22.Google Scholar
  52. 52.
    Hinrichs, C. S., Spolski, R., Paulos, C. M., Gattinoni, L., Kerstann, K. W., Palmer, D. C., Klebanoff, C. A., Rosenberg, S. A., Leonard, W. J., & Restifo, N. P. (2008). IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood., 111(11), 5326–5333.Google Scholar
  53. 53.
    Zhang, E., Gu, J., & Xu, H. (2018). Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors. Molecular Cancer, 17(1), 7.Google Scholar
  54. 54.
    Zhang, Y., & Ertl, H. C. (2016). Starved and asphyxiated: How can CD8+ T cells within a tumor microenvironment prevent tumor progression. Frontiers in Immunology, 7, 32.  https://doi.org/10.3389/fimmu.2016.00032.Google Scholar
  55. 55.
    Maybin, J. A., Murray, A. A., Saunders, P. T., Hirani, N., Carmeliet, P., & Critchley, H. O. (2018). Hypoxia and hypoxia inducible factor-1α are required for normal endometrial repair during menstruation. Nature Communications, 9(1), 295.Google Scholar
  56. 56.
    Juillerat, A., Marechal, A., Filhol, J. M., Valogne, Y., Valton, J., Duclert, A., Duchateau, P., & Poirot, L. (2017). An oxygen sensitive self-decision making engineered CAR T-cell. Scientific Reports, 7, 39833.Google Scholar
  57. 57.
    Jadidi-Niaragh, F., Atyabi, F., Rastegari, A., Kheshtchin, N., Arab, S., Hassannia, H., Ajami, M., Mirsanei, Z., Habibi, S., Masoumi, F., Noorbakhsh, F., Shokri, F., & Hadjati, J. (2017). CD73 specific siRNA loaded chitosan lactate nanoparticles potentiate the antitumor effect of a dendritic cell vaccine in 4T1 breast cancer bearing mice. Journal of Controlled Release, 246, 46–59.Google Scholar
  58. 58.
    Junghans, R. P. (2017). The challenges of solid tumor for designer CAR-T therapies: A 25-years perspective. Nature Publishing Group.  https://doi.org/10.1038/cgt.2016.82.
  59. 59.
    Solinas, G., Schiarea, S., Liguori, M., Fabbri, M., Pesce, S., Zammataro, L., Pasqualini, F., Nebuloni, M., Chiabrando, C., Mantovani, A., & Allavena, P. (2010). Tumor-conditioned macrophages secrete migration-stimulating factor: A new marker for M2-polarization, influencing tumor cell motility. The Journal of Immunology., 185(1), 642–652.Google Scholar
  60. 60.
    Condeelis, J., & Pollard, J. W. (2006). Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis. Cell., 124(2), 263–266.Google Scholar
  61. 61.
    Sharma, P., & Allison, J. P. (2015). Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell., 161(2), 205–214.Google Scholar
  62. 62.
    Jin, C., Yu, D., & Essand, M. (2016). Prospects to improve chimeric antigen receptor T-cell therapy for solid tumors. Future Medicine, 8, 1355–1361.  https://doi.org/10.2217/imt-2016-0125.Google Scholar
  63. 63.
    Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016). The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends in Immunology, 37(3), 208–220.Google Scholar
  64. 64.
    Chinen, T., Kannan, A. K., Levine, A. G., Fan, X., Klein, U., Zheng, Y., Gasteiger, G., Feng, Y., Fontenot, J. D., & Rudensky, A. Y. (2016). An essential role for the IL-2 receptor in T reg cell function. Nature Immunology, 17(11), 1322–1333.Google Scholar
  65. 65.
    Janco, J. M. T., Lamichhane, P., Karyampudi, L., & Knutson, K. L. (2015). Tumor-infiltrating dendritic cells in cancer pathogenesis. The Journal of Immunology., 194(7), 2985–2991.Google Scholar
  66. 66.
    Hurt, B., Schulick, R., Edil, B., El Kasmi, K. C., & Barnett, C. (2017). Cancer-promoting mechanisms of tumor-associated neutrophils. The American Journal of Surgery., 214(5), 938–944.Google Scholar
  67. 67.
    van den Broek, T., Borghans, J. A., & van Wijk, F. (2018). The full spectrum of human naive T cells. Nature Reviews. Immunology, 18, 1–373.  https://doi.org/10.1038/s41577-018-0001-y.Google Scholar
  68. 68.
    Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015). Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell, 27(4), 450–461.Google Scholar
  69. 69.
    Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015). Immune checkpoint blockade in cancer therapy. Journal of Clinical Oncology, 33(17), 1974–1982.Google Scholar
  70. 70.
    Rotte, A., Jin, J., & Lemaire, V. (2017). Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Annals of Oncology, 29(1), 71–83.Google Scholar
  71. 71.
    Linsley, P. S., Greene, J. L., Brady, W., Bajorath, J., Ledbetter, J. A., & Peach, R. (1994). Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity., 1(9), 793–801.Google Scholar
  72. 72.
    Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005). CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Molecular and Cellular Biology, 25(21), 9543–9553.Google Scholar
  73. 73.
    Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008). CTLA-4 control over Foxp3+ regulatory T cell function. Science., 322(5899), 271–275.Google Scholar
  74. 74.
    Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992). Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. The EMBO Journal., 11(11), 3887–3895.Google Scholar
  75. 75.
    Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009). PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. The Journal of Experimental Medicine, 206(13), 3015–3029.Google Scholar
  76. 76.
    Fife, B. T., Pauken, K. E., Eagar, T. N., Obu, T., Wu, J., Tang, Q., Azuma, M., Krummel, M. F., & Bluestone, J. A. (2009). Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal. Nature Immunology, 10(11), 1185–1192.Google Scholar
  77. 77.
    Wang, X., Teng, F., Kong, L., & Yu, J. (2016). PD-L1 expression in human cancers and its association with clinical outcomes. OncoTargets and Therapy., 9, 5023.Google Scholar
  78. 78.
    Chen, N., Morello, A., Tano, Z., & Adusumilli, P. S. (2017). CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy. Oncoimmunology., 6(2), e1273302.Google Scholar
  79. 79.
    Triebel, F., Jitsukawa, S., Baixeras, E., Roman-Roman, S., Genevee, C., Viegas-Pequignot, E., & Hercend, T. (1990). LAG-3, a novel lymphocyte activation gene closely related to CD4. The Journal of Experimental Medicine, 171(5), 1393–1405.Google Scholar
  80. 80.
    Huard, B., Prigent, P., Tournier, M., Bruniquel, D., & Triebel, F. (1995). CD4/major histocompatibility complex class II interaction analyzed with CD4-and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. European Journal of Immunology, 25(9), 2718–2721.Google Scholar
  81. 81.
    Xu, F., Liu, J., Liu, D., Liu, B., Wang, M., Hu, Z., du, X., Tang, L., & He, F. (2014). LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses. Cancer Research, 74(13), 3418–3428.Google Scholar
  82. 82.
    Blackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009). Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nature Immunology, 10(1), 29–37.Google Scholar
  83. 83.
    Zhang, Y., Zhang, X., Cheng, C., Mu, W., Liu, X., Li, N., Wei, X., Liu, X., Xia, C., & Wang, H. (2017). CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells. Frontiers of Medicine., 11(4), 554–562.Google Scholar
  84. 84.
    Prigent, P., El mir, S., Dreano, M., & Triebel, F. (1999). Lymphocyte activation gene-3 induces tumor regression and antitumor immune responses. European Journal of Immunology, 29(12), 3867–3876.Google Scholar
  85. 85.
    Monney, L., Sabatos, C. A., Gaglia, J. L., Ryu, A., Waldner, H., Chernova, T., Manning, S., Greenfield, E. A., Coyle, A. J., Sobel, R. A., Freeman, G. J., & Kuchroo, V. K. (2002). Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature., 415(6871), 536–541.Google Scholar
  86. 86.
    Dardalhon, V., Anderson, A. C., Karman, J., Apetoh, L., Chandwaskar, R., Lee, D. H., Cornejo, M., Nishi, N., Yamauchi, A., Quintana, F. J., Sobel, R. A., Hirashima, M., & Kuchroo, V. K. (2010). Tim-3/galectin-9 pathway: Regulation of Th1 immunity through promotion of CD11b+ Ly-6G+ myeloid cells. The Journal of Immunology., 185(3), 1383–1392.Google Scholar
  87. 87.
    Baitsch, L., Legat, A., Barba, L., Marraco, S. A. F., Rivals, J.-P., Baumgaertner, P., et al. (2012). Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS One, 7(2), e30852.Google Scholar
  88. 88.
    Pasero, C., Speiser, D. E., Derre, L., & Olive, D. (2012). The HVEM network: New directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy. Current Opinion in Pharmacology, 12(4), 478–485.Google Scholar
  89. 89.
    Derré, L., Rivals, J.-P., Jandus, C., Pastor, S., Rimoldi, D., Romero, P., Michielin, O., Olive, D., & Speiser, D. E. (2010). BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. The Journal of Clinical Investigation., 120(1), 157–167.Google Scholar
  90. 90.
    Stanietsky, N., Simic, H., Arapovic, J., Toporik, A., Levy, O., Novik, A., Levine, Z., Beiman, M., Dassa, L., Achdout, H., Stern-Ginossar, N., Tsukerman, P., Jonjic, S., & Mandelboim, O. (2009). The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proceedings of the National Academy of Sciences, 106(42), 17858–17863.Google Scholar
  91. 91.
    Yu, X., Harden, K., Gonzalez, L. C., Francesco, M., Chiang, E., Irving, B., et al. (2009). The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nature Immunology, 10(1), 48–57.Google Scholar
  92. 92.
    Joller, N., Lozano, E., Burkett, P. R., Patel, B., Xiao, S., Zhu, C., Xia, J., Tan, T. G., Sefik, E., Yajnik, V., Sharpe, A. H., Quintana, F. J., Mathis, D., Benoist, C., Hafler, D. A., & Kuchroo, V. K. (2014). Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity., 40(4), 569–581.Google Scholar
  93. 93.
    Levine, D. A., & Network, C. G. A. R. (2013). Integrated genomic characterization of endometrial carcinoma. Nature., 497(7447), 67–73.Google Scholar
  94. 94.
    Network, C. G. A. R. (2012). Comprehensive genomic characterization of squamous cell lung cancers. Nature., 489(7417), 519.Google Scholar
  95. 95.
    Network, C. G. A. (2012). Comprehensive molecular characterization of human colon and rectal cancer. Nature., 487(7407), 330–337.Google Scholar
  96. 96.
    Network, C. G. A. (2012). Comprehensive molecular portraits of human breast tumours. Nature., 490(7418), 61–70.Google Scholar
  97. 97.
    Network, C. G. A. R. (2013). Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature., 499(7456), 43.Google Scholar
  98. 98.
    Casado, J. G., Pawelec, G., Morgado, S., Sanchez-Correa, B., Delgado, E., Gayoso, I., Duran, E., Solana, R., & Tarazona, R. (2009). Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines. Cancer Immunology, Immunotherapy, 58(9), 1517–1526.Google Scholar
  99. 99.
    Ohta, A., Gorelik, E., Prasad, S. J., Ronchese, F., Lukashev, D., Wong, M. K., et al. (2006). A2A adenosine receptor protects tumors from antitumor T cells. Proceedings of the National Academy of Sciences, 103(35), 13132–13137.Google Scholar
  100. 100.
    Ohta, A. (2016). A metabolic immune checkpoint: Adenosine in tumor microenvironment. Frontiers in Immunology, 7, 109.Google Scholar
  101. 101.
    Kmiecik, J., Poli, A., Brons, N. H., Waha, A., Eide, G. E., Enger, P. Ø., et al. (2013). Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. Journal of Neuroimmunology, 264(1), 71–83.Google Scholar
  102. 102.
    Peng, W., Ye, Y., Rabinovich, B. A., Liu, C., Lou, Y., Zhang, M., et al. (2010). Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clinical Cancer Research 1078–0432. CCR-10-712.Google Scholar
  103. 103.
    Spear, P., Barber, A., & Sentman, C. L. (2013). Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors. Oncoimmunology., 2(4), e23564.Google Scholar
  104. 104.
    Chinnasamy, D., Yu, Z., Theoret, M. R., Zhao, Y., Shrimali, R. K., Morgan, R. A., Feldman, S. A., Restifo, N. P., & Rosenberg, S. A. (2010). Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. The Journal of Clinical Investigation., 120(11), 3953–3968.Google Scholar
  105. 105.
    Adusumilli, P. S., Cherkassky, L., Villena-Vargas, J., Colovos, C., Servais, E., Plotkin, J., Jones, D. R., & Sadelain, M. (2014). Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Science Translational Medicine, 6(261), 261ra151–261ra151.Google Scholar
  106. 106.
    Watford, W. T., Moriguchi, M., Morinobu, A., & O’Shea, J. J. (2003). The biology of IL-12: Coordinating innate and adaptive immune responses. Cytokine & Growth Factor Reviews, 14(5), 361–368.Google Scholar
  107. 107.
    Kreso, A., & Dick, J. E. (2014). Evolution of the cancer stem cell model. Cell Stem Cell, 14(3), 275–291.Google Scholar
  108. 108.
    Petrov, J. C., Wada, M., Pinz, K. G., Yan, L. E., Chen, K. H., Shuai, X., Liu, H., Chen, X., Leung, L. H., Salman, H., Hagag, N., Liu, F., Jiang, X., & Ma, Y. (2018). Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia. Leukemia., 32, 1–1326.  https://doi.org/10.1038/s41375-018-0075-3.Google Scholar
  109. 109.
    Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L., Chen, C. C., Yang, J. C., Rosenberg, S. A., & Hwu, P. (2006). A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clinical Cancer Research, 12(20), 6106–6115.Google Scholar
  110. 110.
    Park, J. R., DiGiusto, D. L., Slovak, M., Wright, C., Naranjo, A., Wagner, J., et al. (2007). Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Molecular Therapy, 15(4), 825–833.Google Scholar
  111. 111.
    Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010). Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Molecular Therapy, 18(4), 843–851.Google Scholar
  112. 112.
    Maus, M. V., Haas, A. R., Beatty, G. L., Albelda, S. M., Levine, B. L., Liu, X., Zhao, Y., Kalos, M., & June, C. H. (2013). T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunology Research, 1(1), 26–31.Google Scholar
  113. 113.
    Ahmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., Gray, T., Wu, M. F., Liu, H., Hicks, J., Rainusso, N., Dotti, G., Mei, Z., Grilley, B., Gee, A., Rooney, C. M., Brenner, M. K., Heslop, H. E., Wels, W. S., Wang, L. L., Anderson, P., & Gottschalk, S. (2015). Human epidermal growth factor receptor 2 (HER2)–specific chimeric antigen receptor–modified T cells for the immunotherapy of HER2-positive sarcoma. Journal of Clinical Oncology, 33(15), 1688–1696.Google Scholar
  114. 114.
    Lamers, C. H., Klaver, Y., Gratama, J. W., Sleijfer, S., & Debets, R. (2016). Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells–a completed study overview. Biochemical Society Transactions, 44(3), 951–959.Google Scholar
  115. 115.
    Hege, K. M., Bergsland, E. K., Fisher, G. A., Nemunaitis, J. J., Warren, R. S., McArthur, J. G., et al. (2017). Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. Journal for Immunotherapy of Cancer., 5(1), 22.Google Scholar
  116. 116.
    Ahmed, N., Brawley, V., Hegde, M., Bielamowicz, K., Kalra, M., Landi, D., Robertson, C., Gray, T. L., Diouf, O., Wakefield, A., Ghazi, A., Gerken, C., Yi, Z., Ashoori, A., Wu, M. F., Liu, H., Rooney, C., Dotti, G., Gee, A., Su, J., Kew, Y., Baskin, D., Zhang, Y. J., New, P., Grilley, B., Stojakovic, M., Hicks, J., Powell, S. Z., Brenner, M. K., Heslop, H. E., Grossman, R., Wels, W. S., & Gottschalk, S. (2017). HER2-specific chimeric antigen receptor–modified virus-specific T cells for progressive glioblastoma: A phase 1 dose-escalation trial. JAMA Oncology, 3(8), 1094–1101.Google Scholar
  117. 117.
    Feng, K., Liu, Y., Guo, Y., Qiu, J., Wu, Z., Dai, H., et al. (2018). Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers. Protein & Cell, 2017, 1–10.  https://doi.org/10.1007/s13238-017-0440-4.Google Scholar
  118. 118.
    Zhang, H., Ye, Z.-l., Z-g, Y., Z-q, L., & H-j, J. (2016). New strategies for the treatment of solid tumors with CAR-T cells. International Journal of Biological Sciences, 12(6), 718–729.Google Scholar
  119. 119.
    Newick, K., O'Brien, S., Moon, E., & Albelda, S. M. (2017). CAR T cell therapy for solid tumors. Annual Review of Medicine, 68, 139–152.Google Scholar
  120. 120.
    Brown, C. E., Badie, B., Barish, M. E., Weng, L., Ostberg, J. R., Chang, W.-C., Naranjo, A., Starr, R., Wagner, J., Wright, C., Zhai, Y., Bading, J. R., Ressler, J. A., Portnow, J., D'Apuzzo, M., Forman, S. J., & Jensen, M. C. (2015). Bioactivity and safety of IL13Rα2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clinical Cancer Research, 21(18), 4062–4072.Google Scholar
  121. 121.
    Charlesworth, C. T., Deshpande, P. S., Dever, D. P., Dejene, B., Gomez-Ospina, N., Mantri, S., et al. (2018). Identification of pre-existing adaptive immunity to Cas9 proteins in humans. Biorxiv., 243345.Google Scholar
  122. 122.
    Wu, C.-Y., Roybal, K. T., Puchner, E. M., Onuffer, J., & Lim, W. A. (2015). Remote control of therapeutic T cells through a small molecule–gated chimeric receptor. Science., 350(6258), aab4077.Google Scholar
  123. 123.
    Tamada, K., Geng, D., Sakoda, Y., Bansal, N., Srivastava, R., & Li, Z. (2013). Redirecting gene-modified T cells toward various Cancer types using tagged antibodies (vol 18, pg 6436, 2012). Clinical Cancer Research, 19(4), 951.Google Scholar
  124. 124.
    Urbanska, K., Lanitis, E., Poussin, M., Lynn, R. C., Gavin, B. P., Kelderman, S. et al. (2012). A universal strategy for adoptive immunotherapy of cancer through use of a novel T cell antigen receptor. Cancer Research. 3890.2011.  https://doi.org/10.1158/0008-5472.
  125. 125.
    Liu, L., Sun, M., & Wang, Z. (2012). Adoptive T-cell therapy of B-cell malignancies: Conventional and physiological chimeric antigen receptors. Cancer Letters, 316(1), 1–5.Google Scholar
  126. 126.
    Kahlon, K. S., Brown, C., Cooper, L. J., Raubitschek, A., Forman, S. J., & Jensen, M. C. (2004). Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Research, 64(24), 9160–9166.Google Scholar
  127. 127.
    Shaffer, D. R., Savoldo, B., Yi, Z., Chow, K. K., Kakarla, S., Spencer, D., et al. (2011:blood-2010-04-278218). T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood., 117, 4304–4314.Google Scholar
  128. 128.
    Niederman, T. M., Ghogawala, Z., Carter, B. S., Tompkins, H. S., Russell, M. M., & Mulligan, R. C. (2002). Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proceedings of the National Academy of Sciences, 99(10), 7009–7014.Google Scholar
  129. 129.
    Muniappan, A., Banapour, B., Lebkowski, J., & Talib, S. (2000). Ligand-mediated cytolysis of tumor cells: Use of heregulin-ζ chimeras to redirect cytotoxic T lymphocytes. Cancer Gene Therapy, 7(1), 128–134.Google Scholar
  130. 130.
    Zhang, T., Barber, A., & Sentman, C. L. (2006). Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Cancer Research, 66(11), 5927–5933.Google Scholar
  131. 131.
    Zhang, T., Wu, M.-R., & Sentman, C. L. (2012). An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo. The Journal of Immunology., 1103495.Google Scholar
  132. 132.
    Cho, J. H., Collins, J. J., & Wong, W. W. (2018). Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell., 173, 1426–1438.e11.  https://doi.org/10.1016/j.cell.2018.03.038.Google Scholar
  133. 133.
    Zhao, J., Lin, Q., Song, Y., & Liu, D. (2018). Universal CARs, universal T cells, and universal CAR T cells. Journal of Hematology & Oncology, 11(1), 132.Google Scholar
  134. 134.
    Grada, Z., Hegde, M., Byrd, T., Shaffer, D. R., Ghazi, A., Brawley, V. S., Corder, A., Schönfeld, K., Koch, J., Dotti, G., Heslop, H. E., Gottschalk, S., Wels, W. S., Baker, M. L., & Ahmed, N. (2013). TanCAR: A novel bispecific chimeric antigen receptor for cancer immunotherapy. Molecular Therapy--Nucleic Acids, 2, e105.  https://doi.org/10.1038/mtna.2013.32.Google Scholar
  135. 135.
    Hegde, M., Grada, Z., Pignata, A., Wakefield, A., Fousek, K., Bielamowicz, K., Chow, K., Brawley, V., Byrd, T., Gottschalk, S., Mukherjee, M., Wels, W. S., Baker, M., Dotti, G., Orange, J., & Ahmed, N. (2015). A bispecific chimeric antigen receptor molecule enhances T cell activation through dual immunological synapse formation and offsets antigen escape in glioblastoma. Journal for Immunotherapy of Cancer., 3(S2), O3.Google Scholar
  136. 136.
    Lanitis, E., Poussin, M., Klattenhoff, A. W., Song, D., Sandaltzopoulos, R., June, C. H., & Powell, D. J. (2013). Chimeric antigen receptor T cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunology Research, 1, 43–53.  https://doi.org/10.1158/2326-6066.CIR-13-0008.Google Scholar
  137. 137.
    Wilkie, S., van Schalkwyk, M. C., Hobbs, S., Davies, D. M., van der Stegen, S. J., Pereira, A. C. P., et al. (2012). Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. Journal of Clinical Immunology, 32(5), 1059–1070.Google Scholar
  138. 138.
    Trapani, J. A., Sutton, V. R., Thia, K. Y., Li, Y. Q., Froelich, C. J., Jans, D. A., et al. (2003). A clathrin/dynamin-and mannose-6-phosphate receptor–independent pathway for granzyme B–induced cell death. The Journal of Cell Biology., 160(2), 223–233.Google Scholar
  139. 139.
    Senovilla, L., Vitale, I., Martins, I., Tailler, M., Pailleret, C., Michaud, M., Galluzzi, L., Adjemian, S., Kepp, O., Niso-Santano, M., Shen, S., Marino, G., Criollo, A., Boileve, A., Job, B., Ladoire, S., Ghiringhelli, F., Sistigu, A., Yamazaki, T., Rello-Varona, S., Locher, C., Poirier-Colame, V., Talbot, M., Valent, A., Berardinelli, F., Antoccia, A., Ciccosanti, F., Fimia, G. M., Piacentini, M., Fueyo, A., Messina, N. L., Li, M., Chan, C. J., Sigl, V., Pourcher, G., Ruckenstuhl, C., Carmona-Gutierrez, D., Lazar, V., Penninger, J. M., Madeo, F., Lopez-Otin, C., Smyth, M. J., Zitvogel, L., Castedo, M., & Kroemer, G. (2012). An immunosurveillance mechanism controls cancer cell ploidy. Science., 337(6102), 1678–1684.Google Scholar
  140. 140.
    Martins, I., Tesniere, A., Kepp, O., Michaud, M., Schlemmer, F., Senovilla, L., Séror, C., Métivier, D., Perfettini, J. L., Zitvogel, L., & Kroemer, G. (2009). Chemotherapy induces ATP release from tumor cells. Cell Cycle, 8(22), 3723–3728.Google Scholar
  141. 141.
    Heylmann, D., Bauer, M., Becker, H., Van Gool, S., Bacher, N., Steinbrink, K., et al. (2013). Human CD4+ CD25+ regulatory T cells are sensitive to low dose cyclophosphamide: Implications for the immune response. PLoS One, 8(12), e83384.Google Scholar
  142. 142.
    Matsumura, S., Wang, B., Kawashima, N., Braunstein, S., Badura, M., Cameron TO, et al. (2008). Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. The Journal of Immunology., 181(5), 3099–3107.Google Scholar
  143. 143.
    Ganss, R., Ryschich, E., Klar, E., Arnold, B., & Hämmerling, G. J. (2002). Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Research, 62(5), 1462–1470.Google Scholar
  144. 144.
    Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., Yang, H., Amigorena, S., Ryffel, B., Barrat, F. J., Saftig, P., Levi, F., Lidereau, R., Nogues, C., Mira, J. P., Chompret, A., Joulin, V., Clavel-Chapelon, F., Bourhis, J., André, F., Delaloge, S., Tursz, T., Kroemer, G., & Zitvogel, L. (2007). Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nature Medicine, 13(9), 1050–1059.Google Scholar
  145. 145.
    Aranda, F., Buqué, A., Bloy, N., Castoldi, F., Eggermont, A., Cremer, I., Fridman, W. H., Fucikova, J., Galon, J., Spisek, R., Tartour, E., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2015). Trial watch: Adoptive cell transfer for oncological indications. Oncoimmunology., 4(11), e1046673.Google Scholar
  146. 146.
    Vanneman, M., & Dranoff, G. (2012). Combining immunotherapy and targeted therapies in cancer treatment. Nature Reviews. Cancer, 12(4), 237–251.Google Scholar
  147. 147.
    Ozao-Choy, J., Ma, G., Kao, J., Wang, G. X., Meseck, M., Sung, M., Schwartz, M., Divino, C. M., Pan, P. Y., & Chen, S. H. (2009). The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Research, 69, 2514–2522.  https://doi.org/10.1158/0008-5472.CAN-08-4709.Google Scholar
  148. 148.
    Nishio, N., Diaconu, I., Liu, H., Cerullo, V., Caruana, I., Hoyos, V., Bouchier-Hayes, L., Savoldo, B., & Dotti, G. (2014). Armed oncolytic virus enhances immune functions of chimeric antigen receptor–modified T cells in solid tumors. Cancer Research, 74, 5195–5205.Google Scholar
  149. 149.
    Di Stasi, A., De Angelis, B., Rooney, C. M., Zhang, L., Mahendravada, A., Foster, A. E., et al. (2009). T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood., 113(25), 6392–6402.Google Scholar
  150. 150.
    Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., Kurien, A., Priceman, S. J., Wang, X., Harshbarger, T. L., D’Apuzzo, M., Ressler, J. A., Jensen, M. C., Barish, M. E., Chen, M., Portnow, J., Forman, S. J., & Badie, B. (2016). Regression of glioblastoma after chimeric antigen receptor T-cell therapy. The New England Journal of Medicine, 375(26), 2561–2569.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Safa Tahmasebi
    • 1
  • Reza Elahi
    • 2
  • Abdolreza Esmaeilzadeh
    • 3
    • 4
    Email author
  1. 1.Department of Immunology, Health FacultyTehran University of Medical SciencesTehranIran
  2. 2.School of MedicineZanjan University of Medical SciencesZanjanIran
  3. 3.Department of ImmunologyZanjan University of Medical ScienceZanjanIran
  4. 4.Cancer Gene Therapy Research CenterZanjan University of Medical ScienceZanjanIran

Personalised recommendations